威斯康星州麦迪逊 - 以癌症筛查和诊断测试而闻名的Exact Sciences Corp. (NASDAQ: EXAS)公布了研究结果，显示多癌症早期检测 (MCED)测试取得进展。在圣地亚哥举行的美国癌症研究协会特别会议上展示的研究表明，一种新的多生物标志物方法可以提高癌症检测率，尤其是在早期阶段。

威斯康星州麦迪逊市—Exact Sciences Corp (NASDAQ:EXAS)总裁兼首席执行官Kevin Conroy近期大量购入公司普通股。根据最新的SEC文件显示，Conroy于11月13日以每股51.35美元的价格购入19,500股，总投资额为1,001,325美元。 此次交易使Conroy的直接持股增加到1,074,191股。此外，他还通过退休和信托账户间接持有公司股票，以及683 ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Yale physicist Eduardo H. da Silva Neto led an experiment that supports the existence of a new type of superconductor.

In 2015, the United Nations outlined 17 Sustainable Development Goals (SDGs) aimed at eradicating poverty, protecting our ...

On Friday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $51.48 which represents a decrease of $-1.75 or -3.29% from the prior close of $53.23. The stock opened at $53.14 and ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...

Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.